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EP I L EPSY
Optogenetic and Potassium Channel Gene Therapy in a
Rodent Model of Focal Neocortical Epilepsy
Robert C. Wykes,1* Joost H. Heeroma,1* Laura Mantoan,1* Kaiyu Zheng,1
Douglas C. MacDonald,2 Karl Deisseroth,3 Kevan S. Hashemi,4 Matthew C. Walker,1†
Stephanie Schorge,1† Dimitri M. Kullmann1†
Neocortical epilepsy is frequently drug-resistant. Surgery to remove the epileptogenic zone is only feasible in a
minority of cases, leaving many patients without an effective treatment. We report the potential efficacy of
gene therapy in focal neocortical epilepsy using a rodent model in which epilepsy is induced by tetanus toxin
injection in the motor cortex. By applying several complementary methods that use continuous wireless electro-
encephalographic monitoring to quantify epileptic activity, we observed increases in high frequency activity
and in the occurrence of epileptiform events. Pyramidal neurons in the epileptic focus showed enhanced in-
trinsic excitability consistent with seizure generation. Optogenetic inhibition of a subset of principal neurons
transduced with halorhodopsin targeted to the epileptic focus by lentiviral delivery was sufficient to attenuate
electroencephalographic seizures. Local lentiviral overexpression of the potassium channel Kv1.1 reduced the in-
trinsic excitability of transduced pyramidal neurons. Coinjection of this Kv1.1 lentivirus with tetanus toxin fully pre-
vented the occurrence of electroencephalographic seizures. Finally, administration of the Kv1.1 lentivirus to an
established epileptic focus progressively suppressed epileptic activity over several weeks without detectable
behavioral side effects. Thus, gene therapy in a rodent model can be used to suppress seizures acutely, prevent
their occurrence after an epileptogenic stimulus, and successfully treat established focal epilepsy.
INTRODUCTION
Epilepsy affects more than 50 million people (1). Even with optimal
drug treatment, more than 20% of people with epilepsy continue to
have seizures (2). Intractability is especially common in localization-
related (focal onset) epilepsy (3), where seizures arise from a region or
a neuronal network that is limited to one hemisphere. Such regions
are characterized by abnormalities of anatomy, neuronal connectivity,
synaptic transmission, and/or intrinsic excitability of neurons that lead
to the generation of spontaneous seizures (4). The extent of such a net-
work or region varies, but the area of brain that is indispensable for
the generation of seizures (the epileptogenic zone) is often restricted to
a discrete focus (5).
Although surgical removal of the epileptogenic zone is commonly
used for treatment of mesial temporal lobe epilepsy, it is less successful
in focal neocortical epilepsy, often because proximity to eloquent cor-
tex prevents or restricts the extent of resection (6, 7). Alternative treat-
ments, such as vagal, cortical, or subcortical stimulation; callosotomy;
or ketogenic diet, have met with limited success (8–10). Many patients
continue to have poorly controlled epilepsy, with significant effects on
their health and welfare (11, 12).
Gene therapy targeted to the epileptogenic zone could potentially
alleviate seizures by modifying the activity of neurons at the seizure
focus without permanently excising brain regions or transecting path-
ways. Such therapy could, in principle, be used after a brain insult (such
as a head injury or status epilepticus) to prevent the development of
epilepsy (epileptogenesis) or to stop seizures after epilepsy has been
established. Although eliminating established epilepsy is clinically rel-
evant to a larger target population, previous studies of gene therapy
have concentrated on preventing or retarding epileptogenesis after
status epilepticus, or providing proof of principle of an increased
threshold for provoked seizures (13–19). One study has shown an ef-
fect of gene therapy on progression of chronic epilepsy (20). More-
over, these studies have been restricted to experimental models of
limbic epilepsy or seizures.
We have used a model of chronic refractory focal neocortical epilep-
sy in an eloquent region of the cortex (motor cortex) and developed
a fully automated electroencephalographic (EEG) seizure detection
program to measure the efficacies of three gene therapy strategies
on preventing the evolution of spontaneous seizures, reducing seizure
activity acutely, and treating established epilepsy.
RESULTS
Tetanus toxin injection produces a robust, long-lasting
epileptic focus
We optimized a rat model of refractory neocortical epilepsy (21, 22).
Tetanus toxin injection into the motor cortex is followed by frequent
bursts of epileptiform EEG activity associated with clonic movements
of the face and forelimb. Similar to human epilepsia partialis continua
(23), this seizure activity responds poorly to antiepileptic drugs (22).
We recorded the development of epileptiform activity in the EEG
using a subdural electrode implanted near the injection site and con-
nected to a wireless subcutaneous transmitter able to sample the EEG
at up to 160 Hz continuously for several weeks (24). Within 72 hours
of tetanus toxin injection (10 to 35 ng), we observed bursts of high-
frequency EEG activity, some of which were associated with focal and
secondary generalized seizures (Fig. 1A). The EEG of toxin-injected
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animals also exhibited increased power in the 70- to 160-Hz frequency
range (Fig. 1B), which overlaps with the frequency range (100 to 500 Hz)
of bursts observed in human neocortical epilepsy (25). The number
of high-frequency bursts counted by an observer blinded to the treat-
ment was increased in toxin-injected animals compared to control
animals (Fig. 1C).
The EEG coastline length [the cumulative absolute difference in
voltage between consecutive data points (26)] was also increased in
toxin-injected animals (Fig. 1D) and was strongly correlated with
high-frequency power and observer-counted bursts (figs. S1 and S2).
In association with increased high-frequency power, some injected
animals displayed contralateral forelimb clonus and tonic posturing
(fig. S3). Both burst frequency and clinical seizure severity were cor-
related with tetanus toxin dose (Fig. 1, E and F).
Automated event detection can track epileptogenesis
Because neither high-frequency power nor coastline length is specific
for seizures, we developed a complementary method, which relied on
the detection of sudden increases in ac-
tivity from a recent baseline. The features
of such events were automatically com-
pared to a library of EEG patterns, which
was generated by a supervised learning
algorithm that used concurrent video to
identify increases that genuinely corre-
sponded to seizures. In this way, we could
distinguish electrographic seizure activity
from EEG patterns related to normal be-
havior such as eating and grooming (fig.
S4). Our automated event classification
method uses baseline tracking to compen-
sate for slow trends in EEG power that
can occur with electrode drift caused by
skull thickening with age. The number
of epileptiform events thus detected was
greatly increased in tetanus toxin–injected
animals (Fig. 1G).
Epileptogenesis is associated
with increased intrinsic
neuronal excitability
Epileptic activity peaked around 7 days
after tetanus toxin injection (see below)
and remained elevated for several weeks,
suggesting that our model was robust
and amenable to quantitative assessment
and persists long enough to test gene ther-
apy. The time course further implies that
there is a long-lasting alteration in circuit
or neuronal excitability that outlives the
direct effect of the toxin (27–29). To assess
this, we looked for changes in intrinsic
neuronal excitability in patch-clamp
recordings from motor cortex in ex vivo
slices obtained 1 to 4 weeks after 12.5-ng
tetanus toxin injection. To minimize var-
iability attributable to cell type, we focused
on adapting (type 2) layer 5 pyramidal
neurons (30) (fig. S5). In comparison to control neurons, these cells ex-
hibited a depolarized resting membrane potential (Fig. 2A and fig. S6),
an increased input resistance (Fig. 2B), a decreased current threshold
for evoking action potentials (Fig. 2C), and an increased likelihood of
rebound firing after membrane hyperpolarization (Fig. 2D). They also
exhibited a prolonged afterdepolarization potential after injection of a
0.3-ms depolarizing current at threshold for eliciting an action potential,
and this sometimes resulted in burst firing (Fig. 2, E to G). Tetanus
toxin thus induces a long-lasting increase in the intrinsic excitability
of neurons in the epileptic focus. These changes are qualitatively similar
to intrinsic excitability alterations in other models of epilepsy (31).
Optogenetic inhibition of a subset of neurons acutely
suppresses epileptic activity
We tested whether acute inhibition of a subset of principal neurons in
the focus could reduce network excitability sufficiently to attenuate
electrographic seizure activity. Photoactivation of the chloride pump
halorhodopsin from Natronomonas pharaonis (NpHR) suppresses
Fig. 1. Tetanus toxin injection induces robust changes in EEG activity and neuronal excitability. (A) Rep-
resentative control EEG (Ct, black) and EEG after tetanus toxin injection (TT, red), and EEG recorded
during a secondary generalized seizure (below, red: i, onset; ii, evolution; iii, clonic phase; and iv, post-
ictal period). (B) EEG power 6 to 7 days after tetanus toxin injection (Mann-Whitney: 70 to 120 Hz, P =
0.024; 120 to 160 Hz, P = 0.001; TT dose: mean, 14.2 ng; range, 10 to 35 ng; n = 58; Ct: n = 13). (C)
Number of bursts in 1 hour in Ct and toxin-injected animals (Mann-Whitney P = 0.01). (D) Coastline length
(24-hour average; P = 0.001). (E) High-frequency power (120 to 160 Hz) in Ct and after low and high toxin
dose (low: 10 to 15 ng; high: 17.5 to 35 ng; Kruskal-Wallis P = 0.0001; Dunn’s multiple comparisons: Ct
versus low, P < 0.05; low versus high, P < 0.001). (F) High-frequency power in Ct and in animals without
(TT−) or with overt abnormalities (TT+; fig. S3) (Kruskal-Wallis P < 0.0001; Dunn’s multiple comparisons:
Ct versus TT−, P < 0.01; TT− versus TT+, P < 0.01). (G) Automatically detected epileptiform events in a
24-hour period (Mann-Whitney P < 0.0001). *P < 0.05; **P < 0.01; ***P < 0.001.
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burst firing in organotypic hippocampal cultures (32). We injected
12.5 to 17.5 ng of tetanus toxin into the motor cortex together with
1.25 ml of high-titer lentivirus carrying NpHR 2.0 tagged with enhanced
yellow fluorescent protein (EYFP) under control of a Camk2a promoter
(33). We used two sets of control animals: one group was injected with
NpHR lentivirus alone; the other received tetanus toxin either with a
lentivirus expressing only green fluorescent protein (GFP) or with flu-
orescent beads. Immediately after the injection, a cannula was implanted
at the same site with a 200-mm-diameter optic fiber (Fig. 3A). Seven to
10 days later, a 561-nm laser was connected to the cannula via a fiber-
optic patch cable. We used a 20-s on/20-s off duty cycle for stimulation
to allow NpHR to recover from desensitization and to minimize the
potential disinhibitory effect of depolarization of the g-aminobutyric
acid type A (GABAA) reversal potential caused by intracellular Cl
−
accumulation (34). All experiments and analyses were performed with
the experimenter blinded to the treatment. The EEG and behavior
were monitored for an initial 1000-s baseline period, followed by
1000-s intermittent illumination, and then another 1000-s period after
stopping illumination. The animals were subsequently sacrificed, and
the brains were examined immunohistochemically to confirm trans-
duction of principal neurons (Fig. 3B).
The behavior of the animals was not visibly affected. Laser illumi-
nation in animals coinjected with tetanus toxin and NpHR reduced
epileptiform EEG activity (Fig. 3C). Quantification revealed that illu-
mination significantly reduced high-frequency power (Fig. 3D) and
EEG coastline (Fig. 3E) compared to the 1000-s baseline period. Lower-
frequency (<70 Hz) EEG power was not affected. Finally, the frequency of
automatically detected epileptiform events was significantly reduced by il-
lumination (Fig. 3F). In control animals injected with NpHR alone,
high-frequency power and coastline were lower than in those with
tetanus toxin and indistinguishable from
control animals that received no injection
(Fig. 1). The EEG parameters in these
animals remained unaffected by laser acti-
vation. Animals injected with tetanus toxin
and GFP virus or beads exhibited similar
high-frequency power and coastline as
the experimental group, but these mea-
sures were not affected by illumination.
Optogenetic inhibition thus potential-
ly offers the prospect of aborting seizures
on demand without disrupting interictal
brain function. An advantage of this ap-
proach is that only a restricted area of the
brain needs to be targeted.
Kv1.1 is a potential candidate to
decrease neuronal excitability
The optogenetic attenuation of seizure ac-
tivity raises the possibility that chronic inhi-
bition of a subset of pyramidal cells would
have a long-lasting antiepileptic effect. A
candidate strategy to reverse epileptogenesis
is to overexpress an ion channel that reduces
the increased intrinsic neuronal excitability
observed in the epileptic focus (Fig. 2). Ge-
netic ablation and dendrotoxin-mediated
inhibition of Kv1 potassium channels in-
crease neuronal excitability in a manner qualitatively similar to what we
observed in the tetanus toxin model, including hyperpolarization of the
action potential threshold and increased firing of pyramidal neurons
(35–37). In contrast, lentiviral overexpression of Kv1.1 in cultured neu-
rons increases the current threshold for action potential generation and
reduces the probability of neurotransmitter release (38). We therefore
asked whether lentiviral overexpression of Kv1.1 in vivo also attenuated
the excitability of layer 5 pyramidal neurons in acute brain slices.
Injection of a lentivirus expressing Kv1.1 under a cytomegalovirus
promoter, with a GFP reporter, led to local transduction of layer 5
neurons of the motor cortex (Fig. 4A and fig. S7). Because Kv1.1 over-
expression in interneurons could potentially disinhibit the circuit, we in-
vestigated the cell type specificity of transduction. Co-staining for markers
of glutamatergic, GABAergic, and glial cells [CaMKIIa, GAD67, and
GFAP (glial fibrillary acidic protein), respectively] revealed preferential
transduction of excitatory neurons, with minimal expression of GFP in
interneurons and no detectable expression in glia (fig. S8). Recordings
from GFP-positive layer 5 pyramidal neurons in ex vivo cortical slices
(fig. S9) showed that subthreshold properties including resting mem-
brane potential and input resistance were largely unaffected by Kv1.1
overexpression (Fig. 4, B and C). In contrast, Kv1.1-transduced neurons
required more depolarization to fire action potentials, in particular
trains (Fig. 4, D and E), than either untransduced neurons or neurons
transduced with a control lentivirus expressing GFP alone. In addition,
the relationship of firing frequency to current injection was shifted, with
similar currents eliciting fewer action potentials in Kv1.1-overexpressing
neurons (Fig. 4, F and G). Combined, these effects would be more likely
to attenuate than silence completely neuronal and network activity. We
observed no behavioral deficits in animals overexpressing Kv1.1 in their
primary motor cortex, monitored for 4 weeks after Kv1.1-GFP lentivirus
Fig. 2. Injection of tetanus toxin increases excitability of adapting layer 5 pyramidal neurons. (A to C)
Neurons in toxin-injected animals (TT) were assessed for (A) resting membrane potential (Vm; Mann-
Whitney P = 0.01), (B) input resistance (RN; P = 0.02), and (C) current threshold (Ithresh; P = 0.04). (D)
Representative traces from Ct and TT neurons evoked by −200- and +50-pA current injections. TT
neurons often showed rebound action potentials (7 of 16 versus 0 of 21 in Ct neurons, Fisher’s exact
test P = 0.0011). When the hyperpolarizing current was adjusted to reach the same voltage as in Ct
neurons, 4 of 16 TT neurons showed rebound action potentials (P < 0.05). (E) Sample traces showing
response to 0.3-ms depolarizing current injection sufficient to evoke an action potential. This elicited
two or more action potentials in 5 of 14 TT neurons and 0 of 19 Ct neurons (P = 0.0084). (F and G)
Afterdepolarization parameters in neurons firing only once, showing longer time to peak (P = 0.04) (F)
and decay time constant (P = 0.04) (G) in tetanus toxin–treated animals. *P < 0.05; **P < 0.01.
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injection (fig. S10). When sacrificed at 1 or 4 weeks after injection, we
observed no change in the neuronal marker NeuN and no increase in
GFAP other than that caused by the injection needle (fig. S11).
Overexpression of Kv1.1 can block the development of epilepsy
We next tested whether overexpression of Kv1.1 was sufficient to disrupt
the development of epilepsy. To test this, we coinjected Kv1.1 lentivirus
together with 12.5 ng of tetanus toxin and compared the different mea-
sures of epileptic activity in the EEG. Coinjection of Kv1.1 with tetanus
toxin completely prevented the toxin-induced increase in both high-
frequency EEG power (Fig. 5A) and coastline (Fig. 5, B and C) when com-
pared to animals receiving the same dose of tetanus toxin without Kv1.1.
Kv1.1 also almost completely prevented the occurrence of automatically
detected epileptiform events after tetanus toxin treatment (Fig. 5D). These
data suggest that, as with halorhodopsin, transduction of only a subset
of neurons was sufficient to have robust effects on network activity.
Gene therapy with Kv1.1 can reverse established epilepsy
Can overexpression of Kv1.1 be used to suppress seizure activity after the
epileptic state has become established? To answer this question, we
injected either Kv1.1 lentivirus or GFP-only lentivirus into the seizure
focus 1 week after the 12.5-ng tetanus toxin injection and continued to
record the EEG for several weeks. Compared to animals injected with
GFP, animals receiving the Kv1.1 lentivirus injection showed a reduced
coastline (Fig. 6, A and B) and high-frequency power (Fig. 6C). We also
noted a significant difference of effect of treatment on the number of ep-
ileptiform events between animals injected with Kv1.1 lentivirus and
those injected with GFP alone (Fig. 6D). Indeed, the epileptiform event
frequency returned to baseline after 4 weeks in Kv1.1-treated animals but
remained elevated in animals receiving GFP.
DISCUSSION
This study shows that spontaneous electrographic seizure activity can
be attenuated acutely with an optogenetic strategy and that Kv1.1 gene
Fig. 3. Acute optogenetic attenuation of epileptic activity. (A) Schematic
of the implanted headstage for simultaneous EEG recording and optical
stimulation. (B) Immunohistochemical staining of cells in the focus
showing GFP-containing transduced neurons (left) and CaMKIIa staining
of the same neurons (middle). Right, merged images. (C) Representative
EEG traces before, during, and after 561-nm laser illumination. (D) Mean
high-frequency (HF) power in animals injected with tetanus toxin (TT)
and NpHR lentivirus (left, n= 6), showing a significant decrease upon laser
stimulation (n = 6; Wilcoxon matched pairs signed-rank test, P = 0.03; gray,
individual experiments; purple, mean ± SEM). Baseline high-frequency
power was lower in animals injected with NpHR lentivirus alone (middle;
n = 5; unpaired two-tailed t test, P < 0.001) and unaffected by laser illumina-
tion (yellow,mean±SEM). Laser illuminationhadno effect onhigh-frequency
power in control animals thatwere injectedwith TT togetherwith eitherGFP-
expressing control virus or fluorescent beads (right; n = 8; red, mean ± SEM).
n.s., not significant. (E) Mean coastline length, plotted as in (D), was decreased
by illumination in animals injected with TT and NpHR (Wilcoxon matched
pairs signed-rank test, P = 0.03) but not in control animals injected with TT
and GFP. (F) Automatically detected epileptiform events in the same animals,
plotted as in (D), were decreased upon laser illumination (paired t test after
log transform, P = 0.048). Event counts in animals injected with TT together
with GFP or beads were unaffected by laser illumination (before, 50 ± 25;
during, 47 ± 30; after, 51 ± 40). *P < 0.05.
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therapy both prevents the evolution of spontaneous seizures after an
epileptogenic insult and has a robust therapeutic effect on established
focal neocortical epilepsy.
Many experimental studies of antiepileptic treatments have used
rodent models of seizures precipitated acutely by electrical stimulation
or chemoconvulsants. These are, however, indirectly related to human
epilepsy in which neuronal and network alterations lead to the occur-
rence of spontaneous seizures, and treatment trials in these models
have translated poorly (39). Chronic models of limbic epilepsy have
the advantages that seizures occur spontaneously and that they resem-
ble human epilepsy associated with hippocampal pathology. Although
the epileptogenic zone often involves a distributed network, partial
surgical resection of the temporal lobe can often prevent seizures in
human epilepsy associated with hippocampal sclerosis. We have fo-
cused instead on a model of focal neocortical epilepsy that recapitu-
lates features of epilepsia partialis continua (23). This is a particularly
severe and drug-resistant form of epilepsy characterized by the occur-
rence of continuous or almost continuous
motor seizure activity, for which surgical
resection is often contraindicated by unac-
ceptable risk to motor function. We took
advantage of the tetanus toxin model be-
cause it leads to a stable state characterized
by EEG features similar to those seen in
chronic human focal neocortical epilepsy
(unlike some rodent neocortical seizure
models in which seizures occur only tran-
siently). Both in the human condition and
in the animal model, bursts of high-
frequency EEG activity are associated with
a motor manifestation (22, 23); however,
to minimize mortality and animal suffer-
ing, we mainly used a low dose of tetanus
toxin, which yielded clear EEG changes
but only relatively infrequent overt motor
seizures. Although we have shown that sei-
zure activity in EEG recordings can be re-
duced with lentiviral gene therapy in this
model, it remains to be determined wheth-
er epilepsies with larger or more widely
distributed epileptogenic zones are amena-
ble to such therapies.
Optogenetic inhibition of pyramidal
neurons was sufficient to acutely attenuate
seizure activity in the EEG, underlining
the potential efficacy of a strategy that tar-
gets a neuronal subtype in a discrete area
of the brain, which cannot be achieved with
systemic antiepileptic drugs. Although this
optogenetic approach is invasive, because
of the need to deliver light to the transduced
neurons, it could, in principle, allow seizure
suppression on demand. High-frequency
EEG oscillations build up before neocortical
seizure onset and occur preferentially in
epileptogenic areas (40, 41), suggesting that
automated detection of high-frequency os-
cillations could be used to trigger illumi-
nation via a laser or light-emitting diodes, with potential advantages
over electrical stimulation (8), focal cooling (42), or targeted drug de-
livery (43). This approach offers the prospect of a device analogous to
an implantable defibrillator to stop seizures without permanent alter-
ation of neuronal properties.
For long-term treatment, we focused on Kv1.1 overexpression, which
was well tolerated and suppressed electrographic seizure activity for at
least 4 weeks. Although it was technically difficult to record the EEG
for longer periods, local expression persisted at least 6 months in vivo
(fig. S12), suggesting that the effects of Kv1.1 expression are likely to
persist beyond 4 weeks. Thus far, we have only examined one focal
epilepsy model, but the data indicate that gene therapy using Kv1.1
is potentially curative. We have previously shown that Kv1.1 overex-
pression reduces not only neuronal excitability but also neurotransmit-
ter release from the terminals of transduced neurons in culture (38),
consistent with expression in both somatodendritic and axonal com-
partment. This dual mode of action is potentially advantageous over
Fig. 4. In vivo injection of Kv1.1 lentivirus attenuates excitability of adapting layer 5 pyramidal neu-
rons. (A) GFP expression in a restricted area of motor cortex after injection of Kv1.1-GFP lentivirus.
(B and C) Subthreshold properties in neurons from uninjected animals (UI) and animals injected with GFP-
only lentivirus (G), and in GFP-negative untransduced (UT) and neighboring GFP-positive (Kv) neurons
from Kv1.1-GFP–injected animals [resting membrane potential (RMP) (B) and resting input resistance
(RN) (C)]. (D to G) Neuronal excitability in neurons overexpressing Kv1.1. (D) Action potential threshold
in a train of spikes (P < 0.0005 for an effect of group, linear mixed model analysis). (E) First and fifth action
potentials showing depolarized threshold but no difference in accommodation (spike amplitude, rise time,
decay, and width at half-maximum). (F) Representative traces from neighboring untransduced (black) and
Kv1.1-overexpressing (orange) neurons in response to +200-pA current injection. (G) Frequency-current
relationship showing a significant decrease in firing rate in neurons overexpressing Kv1.1 (P < 0.0001 for
difference between groups, log-linear mixed model). All recordings at 36 ± 1°C, 7 to 20 days after virus
injections. ***P < 0.001.
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other strategies to silence neurons (44): If synaptic inputs to trans-
duced neurons undergo a homeostatic compensation for their reduced
excitability (45), neurotransmitter release from their terminals should
remain attenuated.
Overexpression of Kv1.1 was effective not only in preventing the
development of epilepsy but also in progressively reducing seizure ac-
tivity after epilepsy was established. This suggests that Kv1.1 overexpres-
sion is both antiepileptogenic and antiepileptic. However, lentiviral
treatment blurs the distinction between antiepileptic and anticonvulsant
effects because the decrease in EEG activity was recorded during con-
tinued Kv1.1 overexpression. It will be important to determine wheth-
er conditional expression of Kv1.1 during a finite period could achieve
Fig. 5. Kv1.1 lentivirus injection with tetanus toxin prevents focal neocortical
epileptogenesis. (A) Effect of coinjection of Kv1.1-GFP lentivirus with tetanus
toxin (TT+Kv) on high-frequency power (EEG analyzed over 24 hours, 7 days
after injection; Kruskal-Wallis P < 0.0001, SEM concealed by symbols). (B) Effect
of coinjection of Kv1.1 and tetanus toxin on EEG coastline (P < 0.001). (C) Sam-
ple coastline analysis from 800 s of EEG recorded from three representative
animals 7 days after injection (each point represents the coastline length of a
2-s segment of EEG); arrows indicate expanded EEG traces (top): Ct (black), con-
trol; TT (red), TT-injected animal; TT+Kv (blue), TT + Kv1.1–injected animal. (D)
Effect of Kv1.1 and tetanus toxin coinjection on epileptiform events measured
by automated event classification. Four categories of events are shown with
representative library templates (traces, see also fig. S4; HF short, HF long, HF
low, and HF spike defined in fig. S4). Animals that received Kv1.1 had fewer
epileptiform events than those that received tetanus toxin only (all events
aggregated, log-linear mixedmodel P < 0.001). Kv1.1 injection reduced epilep-
tiform events to rates indistinguishable from Ct animals that did not receive
tetanus toxin (P=0.511). Data aremeans± SEM.Gray area indicates quarantine
period after virus injection. *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 6. Kv1.1 lentivirus treats focal neocortical epilepsy. (A) EEG coastline in
tetanus toxin–treated animals relative to the value at day 7, just before
delayed injection (arrow) of Kv1.1-GFP lentivirus (blue) or GFP-only lentivi-
rus (red). Gray bar indicates quarantine period (linear mixed model, P =
0.004). Below: Numbers of animals at different time points (another control
group without tetanus toxin but injected with GFP lentivirus exhibited no
change in coastline length). (B) Sample EEG traces from two animals at
days 7 and 35 (red, GFP; blue, Kv1.1-GFP). (C) Effect of Kv1.1 injection after
established epileptogenesis on high-frequency power (unpaired t test for
change in power versus GFP, P < 0.05). (D) Effect of Kv1.1 injection after
established epileptogenesis on the number of epileptiform events (log-
linear mixed model for treatment with Kv1.1 versus GFP, P < 0.0001). Red,
tetanus toxin followed by GFP; blue, tetanus toxin followed by Kv1.1; black,
GFP only. *P < 0.05; **P < 0.01; ***P < 0.001.
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similar effects or whether sustained overexpression of Kv1.1 is required
to maintain seizure suppression.
The primary action of tetanus toxin is to cleave the SNARE (soluble
N-ethylmaleimide–sensitive factor attachment protein receptor) pro-
tein synaptobrevin (46), and the depolarization, lowered threshold,
and predisposition to burst firing seen in pyramidal neurons from toxin-
injected animals are likely to be consequences of altered transcription
of multiple channels. Similar increases in intrinsic excitability have been
observed in several other epilepsy models (31), with evidence for changes
in T-type Ca2+ channels (47), hyperpolarization-activated conductance
(48), and A-type K+ channels (49, 50) [see also (51, 52)]. Enhanced in-
trinsic excitability has also been reported in models of neuropathic
pain (53, 54). Kv1.1 overexpression may thus be effective in other dis-
orders characterized by excessive neuronal firing as well as in a wide
range of epilepsy etiologies.
The strategy proposed here for treatment of focal epilepsy does
not preclude surgical resection of the epileptogenic zone. Instead,
local gene therapy potentially offers a less invasive treatment, which,
if unsuccessful, could be followed by definitive resection. However,
where ablative surgery is contraindicated by proximity to eloquent
cortex or critical white matter tracts, we anticipate that the cell type
selectivity and graded effects of gene therapy may make it an attract-
ive option.
MATERIALS AND METHODS
Lentivirus production
For NpHR expression, vesicular stomatitis virus glycoprotein (VSVG)–
pseudotyped lentivirus tagged with EYFP under the Camk2a promoter
(LV-Camk2a-NpHR 2.0-EYFP-WPRE) was produced according to
protocols in the laboratory of M. E. Collins [University College London
(UCL)]. 293FT cells (Invitrogen) were seeded 24 hours before transfec-
tion with the transfer vectors p8.91 (gag/pol expressor) and pMD.G
(VSVG expressor) in FuGENE 6 (Roche), Opti-MEM (Invitrogen), and
sterile TE buffer (Invitrogen). The lentivirus-containing supernatant was
harvested 24, 48, and 72 hours after transfection and centrifuged at
20,000 rpm for 2 hours at 4°C, and the virus was then resuspended,
aliquoted, and stored long term at −80°C. The concentrated viral
titer was determined by quantitative polymerase chain reaction to be
108 infectious units (IU)/ml. High-titer lentivirus (Kv1.1-GFP: pCDH1-
CMV-KCNA1-EF1-copGFP, 2.6 × 109 IU/ml, or GFP only: pCDH1-
CMV-MCS-EF1-copGFP, 1.1 × 109 IU/ml) was obtained from System
Biosciences. The human Kv1.1-GFP lentiviral construct was as de-
scribed in (38). In a subset of animals studied at 4 months, we estimated
that neurons were transduced within a volume of about 0.04 mm3
(NpHR lentivirus) or 0.14 mm3 (Kv1.1 lentivirus).
Tetanus toxin and surgery
Male Sprague-Dawley rats (6 to 12 weeks old) were anesthetized with
isoflurane and placed in a stereotaxic frame (Kopf). Tetanus toxin (gift
of G. Schiavo) was coinjected with lentivirus encoding Kv1.1-GFP,
NpHR, or GFP only or with fluorescent beads (FluoSpheres, 10 mm,
Invitrogen) in a final volume of 1.0 to 1.5 ml into layer 5 of the right
motor cortex (coordinates, 2.4 mm lateral and 0 to 1.0 mm anterior
of bregma at a depth of 1.0 mm from pia). Except where indicated,
12.5 ng of tetanus toxin was injected. An EEG transmitter [A3019D,
Open Source Instruments (24)] was implanted subcutaneously with
a subdural intracranial recording electrode positioned above the
injection site. A reference electrode was implanted in the contra-
lateral skull. For sequential injections, a cannula (Plastics One) was
implanted above the tetanus toxin injection site, and 7 days later, len-
tivirus was administered via the cannula. For optogenetic experiments,
an optic fiber [core diameter, 200 mm; numerical aperture (NA), 0.22;
cannula length, 1.5 to 1.8 mm; Doric Lenses] was implanted above the
injection site. Animals were housed separately in Faraday cages, and
EEG was recorded continuously for up to 6 weeks after surgery. Animal
experiments were conducted in accordance with the Animals (Scientific
Procedures) Act 1986.
EEG analysis
EEG was processed with the Neuroarchiver tool (Open Source Instruments),
which determined EEG power for different frequency bands. EEG epochs
were also exported into LabVIEW (National Instruments) for coastline
analysis. Glitches were excluded if they exceeded 5 × root mean square,
and the signal was high pass–filtered at 10 Hz before calculating the
coastline as the sum of the absolute difference between successive points.
Burst, coastline, and EEG high-frequency power analysis were aver-
aged over 24 hours.
Automated epileptiform event counting
Event sorting is explained in fig. S4. A more complete description of
the seizure detection algorithm with source code is available at http://
www.opensourceinstruments.com/Electronics/A3018/Seizure_Detection.
html#Similarity%20of%20Events.
Optogenetic stimulation in vivo
Optogenetic studies were performed on days 7 to 10 after surgery. The
implanted optic cannula was connected to a 561-nm laser (CrystaLaser)
via a fiber-optic patch cord (NA, 0.22; Doric Lenses) and a rotating com-
mutator (Doric Lenses). The laser output was calibrated with a
digital optical power meter (PM100D, Thorlabs), aiming for an in-
tensity of 25 mW at the implantable fiber tip, corresponding to an
irradiance of about 22 mW/mm2 at a distance of 0.5 to 1 mm, previ-
ously reported to be sufficient to inhibit 98% of spikes in brain slice
experiments (33).
Brain slice preparation
Rats were deeply anesthetized with sodium pentobarbital (intraperi-
toneally) and transcardially perfused with cold (4°C) modified ar-
tificial cerebrospinal fluid (ACSF) containing high sucrose and low
sodium: 85 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 20 mM
NaHCO3, 10 mM Hepes, 25 mM glucose, 75 mM sucrose, 0.5 mM
CaCl2, 4 mM MgCl2, 2 mM kynurenic acid, pH 7.3, oxygenated with
95% O2/5% CO2. The rat was then decapitated, and the brain was rap-
idly removed into cold sucrose–ACSF. Parasagittal slices (300 mm
thick) were prepared with a vibrating slicer (Leica VT 1200S) and
transferred to a holding chamber containing modified ACSF at 35°C.
After 20 min, slices were transferred to a holding chamber containing
ACSF at room temperature: 125 mM NaCl, 2.5 mM KCl, 1.25 mM
NaH2PO4, 20 mM NaHCO3, 5 mM Hepes, 25 mM glucose, 2 mM
CaCl2, 1 mMMgCl2, pH 7.3, oxygenated with 95% O2/5% CO2. Slices
were used for recordings 0.5 to 4 hours after preparation. For recording,
slices were transferred to the stage of an upright microscope equipped
with epifluorescence (Olympus BX51WI) and constantly perfused with
ACSF at 36 ± 1°C.
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Electrophysiology
Somatic whole-cell recordings were obtained under visual control
with infrared difference interference contrast. Pipette resistance was
3 to 5 megohms when filled with intracellular solution. Current-clamp
recordings were obtained with a MultiClamp 700A amplifier (Molecular
Devices) and an intracellular solution containing 135 mM K-gluconate,
4 mM KCl, 10 mM Hepes, 4 mM Mg-ATP, 0.3 mM Na-GTP, 10 mM
Na2-phosphocreatine, 0.01 mM Alexa Fluor 594, and 0.2% (w/v) bio-
cytin (pH 7.3, 291 to 293 mOsm). Layer 5 pyramidal neurons in the
motor cortex were identified by their somatic shape and apical den-
drite and characteristic spiking pattern. Neurons from toxin-injected
animals were patched within the injection site (identified by visu-
alization of the coinjected fluorescent beads or GFP virus). Neurons
expressing either Kv1.1-GFP or GFP only were identified in real time
with PatchVision software (Scientifica). Data were filtered at 4 kHz
and acquired at 50 kHz with a DigiData 1200 series interface board,
with current command routines written in Clampex v9.2 (Molecular
Devices).
Subthreshold properties were measured by injecting 300-ms hyper-
polarizing or depolarizing currents, whose amplitude was increased in
25-pA increments until an action potential was elicited. Action
potential parameters were measured at threshold, and accommodation
was measured when the depolarizing current was increased until at
least 10 spikes were elicited. Frequency-current relationships were ob-
tained from 900-ms current injections. Afterdepolarization parameters
(amplitude, duration, and decay) were measured by injecting a 0.3-ms
current whose amplitude was gradually increased until at least one
action potential was elicited.
Electrophysiological data were analyzed offline in IGOR Pro v6.0
(WaveMetrics) with routines originally written by J. Waters (Northwest-
ern University) and adapted by I. Oren (UCL) and R.W. (55). Input re-
sistance at rest was estimated from the slope at 0 pA of a quadratic fit to a
plot of steady-state voltage against current at the end of a 300-ms current
injection, after relaxation of sag potentials. Action potential threshold
was defined as the point where dV/dt first exceeded 40 mV/ms. The initial
interspike interval used to assess adaptation was taken from the time be-
tween the thresholds of the second and the third spikes. The decay of
the afterdepolarization was estimated from a monoexponential fit to
the relaxation of the membrane potential.
Motor behavior
Rats injected with either Kv1.1-GFP or GFP-only lentivirus into the
right motor cortex (volume and coordinates as above) were assessed
with a grid-walking test (56). Each animal was placed on a 52 × 32–cm
elevated horizontal platform consisting of a square painted steel wire
array (4-cm spacing) and allowed to explore the arena for 2 min.
Two observers blinded to the lentiviral treatment independently scored
the number of forelimb foot faults (where the entire foot passed through
the gap). The test was applied before the lentiviral treatment and then at
weekly intervals for 4 weeks.
Immunohistochemistry
Animals were transcardially perfused under terminal anesthesia (so-
dium pentobarbital) with heparinized phosphate-buffered saline (PBS)
(10 U of heparin/ml of PBS), followed by 4% paraformaldehyde
(PFA)/PBS. Brains were removed and left in 4% PFA/PBS overnight
at 4°C and then washed in PBS. Parasagittal and coronal slices (30 to
150 mm thickness) were cut on a vibrating slicer or freezing vibratome
(both Leica Microsystems) and mounted on microscope slides (Thermo
Scientific) with polyvinyl alcohol mounting medium with DABCO
antifading reagent (Sigma), Vectashield (Vector Labs), or Mowiol
(Polysciences Inc.) mounting medium. Bright-field and fluorescence
images were analyzed and assembled with ImageJ software (MosaicJ
plugin). For characterization of the expression of NpHR, sections were
permeabilized in PBS and 0.2% Triton X-100 for 10 min and then
blocked with DAKO-blocking medium (Dako) for 1 hour on a shaker.
Subsequently, they were incubated for 2 days in primary antibodies
against CaMKIIa (1:100 to 1:200, Thermo Scientific) and GFP (1:3000,
Abcam, ab13970, or 1:800, Aves Labs, GFP-1020). After further washes
in PBS, the sections were incubated in secondary antibodies (1:1000,
Abcam, and labeled with Alexa Fluor 488, Alexa Fluor 568, or tetra-
methylrhodamine) overnight at 4°C. Sections were then incubated in
4′,6-diamidino-2-phenylindole to identify nuclei. For Kv1.1 lentivirus–
injected animals, slices were permeabilized in PBS with 0.3% Triton
X-100 (PBST), blocked in 4% normal goat serum, and incubated over-
night in mouse anti-CaMKIIa (1:200), mouse anti-GAD67 (1:500),
mouse anti-GFAP, or mouse anti-NeuN (1:200 or 1:400, mab05-532,
mab5406, mab3402, and mab377, respectively; Millipore) in PBST. Af-
ter washing in PBS, slices were incubated for 2 hours at room tempera-
ture in goat anti-mouse Alexa Fluor 546 (1:1000, Invitrogen). After 3 ×
20–min washes in PBS, the slices were mounted in polyvinyl alcohol–
DABCO or Vectashield. Images were obtained with a Zeiss LSM 510 or
710 confocal microscope, or a Leica DM5000B upright fluorescence mi-
croscope at ×10 magnification and a Leica DM2500 upright confocal
microscope at ×40 magnification. The spatial extent of viral expression
was estimated by multiplying the slice thickness with the size of the area
exhibiting EYFP fluorescence at ×10 magnification, and summing over
consecutive slices. Image analysis and cell counting were performed
with GIMP and ImageJ.
Statistical analysis
Paired or unpaired parametric or nonparametric t tests or analysis of
variances (ANOVAs) were performed as appropriate with InStat V3
software (GraphPad). For analysis of time series data or repeated mea-
sures, we used generalized mixed linear model analysis (SPSS version
12). For counts of epileptiform events after treatment, we used a log-linear
model with random effect of day (autoregressive covariance) and fixed
effect of the interaction between treatment group and time receiving
treatment. For analysis of change in coastline after treatment, we used
a linear model with random effect of day (autoregressive covariance)
and fixed effect of treatment group. Action potential threshold and
frequency (counts) were analyzed with a linear mixed model and a
log-linear mixed model, respectively.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/4/161/161ra152/DC1
Fig. S1. Correlation of EEG coastline length with increases in high-frequency power.
Fig. S2. Correlation of burst counting by a blinded observer with high-frequency power and
coastline length.
Fig. S3. Electroclinical features of the tetanus toxin model.
Fig. S4. Automated event classification.
Fig. S5. Criteria used to identify adapting layer 5 pyramidal neurons.
Fig. S6. Biophysical properties of type 2 pyramidal neurons in animals injected tetanus toxin.
Fig. S7. Estimation of volume of tissue transduced with Kv1.1-GFP lentivirus.
Fig. S8. Preferential transduction of excitatory neurons with Kv1.1 lentivirus.
Fig. S9. Identification of layer 5 neurons.
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Fig. S10. Behavioral assessment in animals injected with Kv1.1-GFP lentivirus.
Fig. S11. Immunohistochemical analysis of neuronal and glial markers after Kv1.1-GFP lentivi-
rus injection.
Fig. S12. Stable neuronal transduction with Kv1.1 lentivirus.
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Abstracts
One-sentence summary: Light-activated gene therapy acutely suppresses seizures, and gene therapy with a
potassium channel prevents epileptogenesis and treats established epilepsy in a rodent model.
Editor’s Summary:
Casting Light on the Shadow of Epilepsy
Epilepsy affects 1% of the population and is often resistant to medication. Surgery to remove the region of the brain
that generates seizures is only feasible in a minority of cases because of risks to movement, language, vision, and
other essential functions. There is an urgent need for alternative treatments. In a new study, Wykes et al. used a virus
to express a therapeutic gene in a small number of brain neurons in the seizure-generating zone in a rat model of
drug-resistant epilepsy. They also developed new wireless technology to monitor and detect seizures using a min-
iaturized implanted transmitter and advanced algorithms. They took two approaches to reduce brain circuit excit-
ability and hence epileptic seizures in the rat model. First, to suppress neuronal firing acutely, they expressed the
light-sensitive chloride transporter halorhodopsin in the seizure-generating zone. When laser light was delivered via
an optic fiber to this region and the halorhodopsin was activated, they observed a decrease in electrical seizure ac-
tivity. The success of this “optogenetic” approach implies that a device could be developed to detect and stop seizures
“on demand” akin to an implantable defibrillator for heart rhythm disturbances. For longer-term suppression of
epilepsy, the investigators overexpressed a brain potassium ion channel that normally regulates both neuronal ex-
citability and neurotransmitter release. This gene therapy treatment fully prevented epilepsy from developing in the
rat model. When it was applied during established epilepsy, potassium channel gene therapy progressively
diminished the frequency of seizures until they stopped after a few weeks. Neither of the gene therapy approaches
tested interfered with normal behavior, most likely because only a small number of neurons were targeted. Although
still in the earliest stages of study, this gene therapy approach may hold promise for treating drug-resistant epilepsy.
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